Gerstberger, S., Hafner, M. & Tuschl, T. A census of human RNA-binding proteins. Nat. Rev. Genet. 15, 829–845 (2014).
Castello, A. et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell 149, 1393–1406 (2012).
Neelamraju, Y., Hashemikhabir, S. & Janga, S. C. The human RBPome: from genes and proteins to human disease. J. Proteom. 127, 61–70 (2015).
Zigdon, I. et al. Beyond RNA-binding domains: determinants of protein-RNA binding. RNA 30, 1620–1633 (2024).
Dreyfuss, G. Structure and function of nuclear and cytoplasmic ribonucleoprotein particles. Annu. Rev. Cell Biol. 2, 459–498 (1986).
Singh, G., Pratt, G., Yeo, G. W. & Moore, M. J. The clothes make the mRNA: past and present trends in mRNP Fashion. Annu. Rev. Biochem. 84, 325–354 (2015).
Lunde, B. M., Moore, C. & Varani, G. RNA-binding proteins: modular design for efficient function. Nat. Rev. Mol. Cell Biol. 8, 479–490 (2007).
Hentze, M. W., Castello, A., Schwarzl, T. & Preiss, T. A brave new world of RNA-binding proteins. Nat. Rev. Mol. Cell Biol. 19, 327–341 (2018).
Giambruno, R., Grzybowska, E. A., Fawzi, N. L. & Dormann, D. Editorial: The role of protein post-translational modifications in protein-RNA interactions and RNP assemblies. Front. Mol. Biosci. 8, 831810 (2021).
England, W. E. et al. An atlas of posttranslational modifications on RNA binding proteins. Nucleic Acids Res. 50, 4329–4339 (2022).
García-Mauriño, S. M. et al. RNA binding protein regulation and cross-talk in the control of AU-rich mRNA fate. Front. Mol. Biosci. 4, 71 (2017).
Grammatikakis, I., Abdelmohsen, K. & Gorospe, M. Posttranslational control of HuR function. Wiley Interdiscip. Rev. RNA 8, e1372 https://doi.org/10.1002/wrna.1372 (2017).
Qin, H. et al. RNA-binding proteins in tumor progression. J. Hematol. Oncol. 13, 90 (2020).
Kang, D., Lee, Y. & Lee, J. S. RNA-binding proteins in cancer: functional and therapeutic perspectives. Cancers 12, 2699 (2020).
Wang, Z. L. et al. Comprehensive genomic characterization of RNA-binding proteins across human cancers. Cell Rep. 22, 286–298 (2018).
Hong, S. RNA binding protein as an emerging therapeutic target for cancer prevention and treatment. J. Cancer Prev. 22, 203–210 (2017).
Tang, L. et al. Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance. Cell Commun. Signal. 22, 513 (2024).
Cerneckis, J., Ming, G. L., Song, H., He, C. & Shi, Y. The rise of epitranscriptomics: recent developments and future directions. Trends Pharmacol. Sci. 45, 24–38 (2024).
Meisner, N. C. et al. Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR. Nat. Chem. Biol. 3, 508–515 (2007).
Wu, X. et al. Identification and validation of novel small molecule disruptors of HuR-mRNA interaction. ACS Chem. Biol. 10, 1476–1484 (2015).
Blanco, F. F. et al. Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis. Oncotarget 7, 74043–74058 (2016).
Stöhr, N. et al. IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling. Genes Dev. 26, 176–189 (2012).
Viswanathan, S. R. et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat. Genet. 41, 843–848 (2009).
Yu, F. et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131, 1109–1123 (2007).
Li, A. et al. Using the structural diversity of RNA: protein interfaces to selectively target RNA with small molecules in cells: methods and perspectives. Front. Mol. Biosci. 10, 1298441 (2023).
Mir, C., Garcia-Mayea, Y. & ME, L. L. Targeting the ‘undruggable’: RNA-binding proteins in the spotlight in cancer therapy. Semin. Cancer Biol. 86, 69–83 (2022).
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).
Gao, M., Nakajima An, D., Parks, J. M. & Skolnick, J. AF2Complex predicts direct physical interactions in multimeric proteins with deep learning. Nat. Commun. 13, 1744 (2022).
Ruffolo, J. A., Chu, L. S., Mahajan, S. P. & Gray, J. J. Fast, accurate antibody structure prediction from deep learning on massive set of natural antibodies. Nat. Commun. 14, 2389 (2023).
Neklesa, T. K., Winkler, J. D. & Crews, C. M. Targeted protein degradation by PROTACs. Pharmacol. Ther. 174, 138–144 (2017).
George, B. M. et al. Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding protein. Nat. Biotechnol. 44, 430–443 (2025).
Perr, J. et al. RNA-binding proteins and glycoRNAs form domains on the cell surface for cell-penetrating peptide entry. Cell 188, 1878–1895 (2025).
Knorr, K. et al. Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia. Nat. Cancer 4, 1675–1692 (2023).
Lerner, M. R. & Steitz, J. A. Antibodies to small nuclear RNAs complexed with proteins are produced by patients with systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 76, 5495–5499 (1979).
Lerner, M. R., Boyle, J. A., Hardin, J. A. & Steitz, J. A. Two novel classes of small ribonucleoproteins detected by antibodies associated with lupus erythematosus. Science 211, 400–402 (1981).
Wolin, S. L. & Steitz, J. A. The Ro small cytoplasmic ribonucleoproteins: identification of the antigenic protein and its binding site on the Ro RNAs. Proc. Natl Acad. Sci. USA 81, 1996–2000 (1984).
Adam, S. A., Nakagawa, T., Swanson, M. S., Woodruff, T. K. & Dreyfuss, G. mRNA polyadenylate-binding protein: gene isolation and sequencing and identification of a ribonucleoprotein consensus sequence. Mol. Cell. Biol. 6, 2932–2943 (1986).
Swanson, M. S., Nakagawa, T. Y., LeVan, K. & Dreyfuss, G. Primary structure of human nuclear ribonucleoprotein particle C proteins: conservation of sequence and domain structures in heterogeneous nuclear RNA, mRNA, and pre-rRNA-binding proteins. Mol. Cell. Biol. 7, 1731–1739 (1987).
Tenenbaum, S. A., Carson, C. C., Lager, P. J. & Keene, J. D. Identifying mRNA subsets in messenger ribonucleoprotein complexes by using cDNA arrays. Proc. Natl Acad. Sci. USA 97, 14085–14090 (2000).
Gerstberger, S., Hafner, M., Ascano, M. & Tuschl, T. Evolutionary conservation and expression of human RNA-binding proteins and their role in human genetic disease. Adv. Exp. Med. Biol. 825, 1–55 (2014).
Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).
Lin, Y. et al. Unveiling the veil of RNA binding protein phase separation in cancer biology and therapy. Cancer Lett. 601, 217160 (2024).
Ivanov, P., Kedersha, N. & Anderson, P. Stress granules and processing bodies in translational control. Cold Spring Harb. Perspect. Biol. 11, a032813 (2019).
Liu, J. et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305, 1437–1441 (2004).
Laggerbauer, B., Achsel, T. & Lührmann, R. The human U5-200kD DEXH-box protein unwinds U4/U6 RNA duplices in vitro. Proc. Natl Acad. Sci. USA 95, 4188–4192 (1998).
Yu, Z. et al. DDX5 resolves R-loops at DNA double-strand breaks to promote DNA repair and avoid chromosomal deletions. NAR Cancer 2, zcaa028 (2020).
Calo, E. et al. RNA helicase DDX21 coordinates transcription and ribosomal RNA processing. Nature 518, 249–253 (2015).
Ginisty, H., Amalric, F. & Bouvet, P. Nucleolin functions in the first step of ribosomal RNA processing. EMBO J. 17, 1476–1486 (1998).
Maggi, L. B. et al. Nucleophosmin serves as a rate-limiting nuclear export chaperone for the mammalian ribosome. Mol. Cell. Biol. 28, 7050–7065 (2008).
Seweryn, E. et al. A. Localization of enolase in the subfractions of a breast cancer cell line. Z. Naturforsch C. J. Biosci. 64, 754–758 (2009).
Didiasova, M. et al. STIM1/ORAI1-mediated Ca2+ influx regulates enolase-1 exteriorization. J. Biol. Chem. 290, 11983–11999 (2015).
Cappello, P. et al. An integrated humoral and cellular response is elicited in pancreatic cancer by α-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int. J. Cancer 125, 639–648 (2009).
Chang, G.-C. et al. Identification of α-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin. Cancer Res. 12, 5746–5754 (2006).
Wang, N. et al. RNA-binding protein ENO1 promotes the tumor progression of gastric cancer by binding to and regulating gastric cancer-related genes. J. Gastrointest. Oncol. 14, 585–598 (2023).
De Conti, L., Baralle, M. & Buratti, E. Exon and intron definition in pre-mRNA splicing. Wiley Interdiscip. Rev. RNA 4, 49–60 (2013).
Fu, X. D. & Ares, M. Context-dependent control of alternative splicing by RNA-binding proteins. Nat. Rev. Genet. 15, 689–701 (2014).
Papasaikas, P., Tejedor, J. R., Vigevani, L. & Valcarcel, J. Functional splicing network reveals extensive regulatory potential of the core spliceosomal machinery. Mol. Cell 57, 7–22 (2015).
Raj, B. et al. A global regulatory mechanism for activating an exon network required for neurogenesis. Mol. Cell 56, 90–103 (2014).
Chen, M. & Manley, J. L. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat. Rev. Mol. Cell Biol. 10, 741–754 (2009).
Erkelenz, S. et al. Position-dependent splicing activation and repression by SR and hnRNP proteins rely on common mechanisms. RNA 19, 96–102 (2013).
Ibrahim, E. C., Schaal, T. D., Hertel, K. J., Reed, R. & Maniatis, T. Serine/arginine-rich protein-dependent suppression of exon skipping by exonic splicing enhancers. Proc. Natl Acad. Sci. USA 102, 5002–5007 (2005).
Abovich, N. & Rosbash, M. Cross-intron bridging interactions in the yeast commitment complex are conserved in mammals. Cell 89, 403–412 (1997).
Ule, J. & Blencowe, B. J. Alternative splicing regulatory networks: functions, mechanisms, and evolution. Mol. Cell 76, 329–345 (2019).
Zhong, X. Y., Wang, P., Han, J., Rosenfeld, M. G. & Fu, X. D. SR proteins in vertical integration of gene expression from transcription to RNA processing to translation. Mol. Cell 35, 1–10 (2009).
Pinol-Roma, S. & Dreyfuss, G. Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm. Nature 355, 730–732 (1992).
Moulton, V. R., Gillooly, A. R. & Tsokos, G. C. Ubiquitination regulates expression of the serine/arginine-rich splicing factor 1 (SRSF1) in normal and systemic lupus erythematosus (SLE) T cells. J. Biol. Chem. 289, 4126–4134 (2014).
Hofmann, Y. & Wirth, B. hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-β1. Hum. Mol. Genet. 11, 2037–2049 (2002).
Chen, H. H., Chang, J. G., Lu, R. M., Peng, T. Y. & Tarn, W. Y. The RNA binding protein hnRNP Q modulates the utilization of exon 7 in the survival motor neuron 2 (SMN2) gene. Mol. Cell. Biol. 28, 6929–6938 (2008).
Kashima, T. & Manley, J. L. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat. Genet. 34, 460–463 (2003).
Ratni, H. et al. Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J. Med. Chem. 61, 6501–6517 (2018).
Ratni, H., Scalco, R. S. & Stephan, A. H. Risdiplam, the first approved small molecule splicing modifier drug as a blueprint for future transformative medicines. ACS Med. Chem. Lett. 12, 874–877 (2021).
Campagne, S. et al. Structural basis of a small molecule targeting RNA for a specific splicing correction. Nat. Chem. Biol. 15, 1191–1198 (2019).
Kemal, R. A. & O’Keefe, R. T. Addressing the tissue specificity of U5 snRNP spliceosomopathies. Front. Cell Dev. Biol. 13, 1572188 (2025).
Liu, X.-Y. et al. Regulation of RAGE splicing by hnRNP A1 and Tra2β-1 and its potential role in AD pathogenesis. J. Neurochem. 133, 187–198 (2015).
Zearfoss, N. R., Johnson, E. S. & Ryder, S. P. hnRNP A1 and secondary structure coordinate alternative splicing of Mag. RNA 19, 948–957 (2013).
Zuker, M. On finding all suboptimal foldings of an RNA molecule. Science 244, 48–52 (1989).
Timsit, Y., Sergeant-Perthuis, G. & Bennequin, D. Evolution of ribosomal protein network architectures. Sci. Rep. 11, 625 (2021).
Catalanotto, C., Barbato, C., Cogoni, C. & Benelli, D. The RNA-binding function of ribosomal proteins and ribosome biogenesis factors in human health and disease. Biomedicines 11, 2969 (2023).
Flygare, J. et al. Human RPS19, the gene mutated in Diamond-Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunits. Blood 109, 980–986 (2007).
Ulirsch, J. C. et al. The genetic landscape of Diamond-Blackfan anemia. Am. J. Hum. Genet. 104, 356 (2019).
Okuwaki, M., Saito, S., Hirawake-Mogi, H. & Nagata, K. The interaction between nucleophosmin/NPM1 and the large ribosomal subunit precursors contribute to maintaining the nucleolar structure. Biochim. Biophys. Acta Mol. Cell Res. 1868, 118879 (2021).
Smith, R. W., Blee, T. K. & Gray, N. K. Poly(A)-binding proteins are required for diverse biological processes in metazoans. Biochem. Soc. Trans. 42, 1229–1237 (2014).
Mitchell, S. A. et al. Identification of a motif that mediates polypyrimidine tract-binding protein-dependent internal ribosome entry. Genes Dev. 19, 1556–1571 (2005).
Mura, M. et al. LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression. Oncogene 34, 5025–5036 (2015).
Jankowsky, E. RNA helicases at work: binding and rearranging. Trends Biochem. Sci. 36, 19–29 (2011).
Anantharaman, V., Koonin, E. V. & Aravind, L. Comparative genomics and evolution of proteins involved in RNA metabolism. Nucleic Acids Res. 30, 1427–1464 (2002).
Skourti-Stathaki, K., Proudfoot, N. J. & Gromak, N. Human senataxin resolves RNA/DNA hybrids formed at transcriptional pause sites to promote Xrn2-dependent termination. Mol. Cell 42, 794–805 (2011).
Shen, H. et al. Distinct activities of the DExD/H-box splicing factor hUAP56 facilitate stepwise assembly of the spliceosome. Genes Dev. 22, 1796–1803 (2008).
Perriman, R. J. & Ares, M. Rearrangement of competing U2 RNA helices within the spliceosome promotes multiple steps in splicing. Genes Dev. 21, 811–820 (2007).
Andersen, C. B. F. et al. Structure of the exon junction core complex with a trapped DEAD-box ATPase bound to RNA. Science 313, 1968–1972 (2006).
Snay-Hodge, C. A., Colot, H. V., Goldstein, A. L. & Cole, C. N. Dbp5p/Rat8p is a yeast nuclear pore-associated DEAD-box protein essential for RNA export. EMBO J. 17, 2663–2676 (1998).
Montpetit, B. et al. A conserved mechanism of DEAD-box ATPase activation by nucleoporins and InsP6 in mRNA export. Nature 472, 238–242 (2011).
Merrick, W. C. eIF4F: a retrospective. J. Biol. Chem. 290, 24091–24099 (2015).
Lingaraju, M. et al. The MTR4 helicase recruits nuclear adaptors of the human RNA exosome using distinct arch-interacting motifs. Nat. Commun. 10, 3393 (2019).
Kim, Y. K. & Maquat, L. E. UPFront and center in RNA decay: UPF1 in nonsense-mediated mRNA decay and beyond. RNA 25, 407–422 (2019).
Cloutier, S. C. et al. Regulated formation of lncRNA-DNA hybrids enables faster transcriptional induction and environmental adaptation. Mol. Cell 61, 393–404 (2016).
Martin, R., Straub, A. U., Doebele, C. & Bohnsack, M. T. DExD/H-box RNA helicases in ribosome biogenesis. RNA Biol. 10, 4–18 (2013).
Sanghai, Z. A. et al. Modular assembly of the nucleolar pre-60S ribosomal subunit. Nature 556, 126–129 (2018).
Kater, L. et al. Visualizing the assembly pathway of nucleolar pre-60S ribosomes. Cell 171, 1599–1610 (2017).
Soifer, H. S. et al. A role for the dicer helicase domain in the processing of thermodynamically unstable hairpin RNAs. Nucleic Acids Res. 36, 6511–6522 (2008).
Popow, J., Jurkin, J., Schleiffer, A. & Martinez, J. Analysis of orthologous groups reveals archease and DDX1 as tRNA splicing factors. Nature 511, 104–107 (2014).
Rehwinkel, J. & Gack, M. U. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat. Rev. Immunol. 20, 537–551 (2020).
Jain, S. et al. ATPase-modulated stress granules contain a diverse proteome and substructure. Cell 164, 487–498 (2016).
Hoffmann, H. J., Wenkel, R., Schicknick, H., Bernstein, H. G. & Schwegler, H. Hippocampal mossy fiber distribution does not correlate with two-way active avoidance performance in backcross lines derived from inbred mouse strains DBA/2 and C3H. Brain Res. 589, 171–174 (1992).
Bohnsack, K. E., Yi, S., Venus, S., Jankowsky, E. & Bohnsack, M. T. Cellular functions of eukaryotic RNA helicases and their links to human diseases. Nat. Rev. Mol. Cell Biol. 24, 749–769 (2023).
Ali, M. A. M. DEAD-box RNA helicases: the driving forces behind RNA metabolism at the crossroad of viral replication and antiviral innate immunity. Virus Res. 296, 198352 (2021).
Smyth, D. J. et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat. Genet. 38, 617–619 (2006).
Cheng, Y. et al. Aberrant expression of the UPF1 RNA surveillance gene disturbs keratinocyte homeostasis by stabilizing AREG. Int. J. Mol. Med. 45, 1163–1175 (2020).
Eckard, S. C. et al. The SKIV2L RNA exosome limits activation of the RIG-I-like receptors. Nat. Immunol. 15, 839–845 (2014).
Richard, P., Feng, S. & Manley, J. L. A SUMO-dependent interaction between Senataxin and the exosome, disrupted in the neurodegenerative disease AOA2, targets the exosome to sites of transcription-induced DNA damage. Genes Dev. 27, 2227–2232 (2013).
Hirano, M. et al. Senataxin mutations and amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 12, 223–227 (2011).
Sun, Y., Eshov, A., Zhou, J., Isiktas, A. U. & Guo, J. U. C9orf72 arginine-rich dipeptide repeats inhibit UPF1-mediated RNA decay via translational repression. Nat. Commun. 11, 3354 (2020).
Fagre, C. & Gilbert, W. Beyond reader proteins: RNA binding proteins and RNA modifications in conversation to regulate gene expression. Wiley Interdiscip. Rev. RNA 15, e1834 (2024).
Zhang, L., Wei, J., Zou, Z. & He, C. RNA modification systems as therapeutic targets. Nat. Rev. Drug Discov. 25, 59–78 (2025).
Jia, G. et al. N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat. Chem. Biol. 7, 885–887 https://doi.org/10.1038/nchembio.687 (2011).
Jiang, X. et al. The role of m6A modification in the biological functions and diseases. Signal Transduct. Target. Ther. 6, 74 (2021).
Peng, H. et al. N6-Methyladenosine (m6A) in 18S rRNA promotes fatty acid metabolism and oncogenic transformation. Nat. Metab. 4, 1041–1054 (2022).
Zeng, C., Huang, W., Li, Y. & Weng, H. Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J. Hematol. Oncol. 13, 117 (2020).
Deng, X., Qing, Y., Horne, D., Huang, H. & Chen, J. The roles and implications of RNA m6A modification in cancer. Nat. Rev. Clin. Oncol. 20, 507–526 (2023).
Luo, Q. et al. Decreased ALKBH5, FTO, and YTHDF2 in peripheral blood are as risk factors for rheumatoid arthritis. Biomed. Res. Int. 2020, 5735279 (2020).
Du, T. et al. An association study of the m6A genes with major depressive disorder in Chinese Han population. J. Affect. Disord. 183, 279–286 (2015).
Fischer, J. et al. Inactivation of the Fto gene protects from obesity. Nature 458, 894–898 (2009).
Church, C. et al. Overexpression of Fto leads to increased food intake and results in obesity. Nat. Genet. 42, 1086–1092 (2010).
Hess, M. E. et al. The fat mass and obesity associated gene (Fto) regulates activity of the dopaminergic midbrain circuitry. Nat. Neurosci. 16, 1042–1048 (2013).
Frayling, T. M. et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316, 889–894 (2007).
Scott, L. J. et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316, 1341–1345 (2007).
Dina, C. et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat. Genet. 39, 724–726 (2007).
Zhang, X., Zhu, W. Y., Shen, S. Y., Shen, J. H. & Chen, X. D. Biological roles of RNA m7G modification and its implications in cancer. Biol. Direct 18, 58 (2023).
Alexandrov, A., Martzen, M. R. & Phizicky, E. M. Two proteins that form a complex are required for 7-methylguanosine modification of yeast tRNA. RNA 8, 1253–1266 (2002).
Zhao, Z. et al. QKI shuttles internal m7G-modified transcripts into stress granules and modulates mRNA metabolism. Cell 186, 3208–3226.e27 (2023).
Liu, C. et al. IGF2BP3 promotes mRNA degradation through internal m7G modification. Nat. Commun. 15, 7421 (2024).
Li, J. et al. Structural basis of regulated m7G tRNA modification by METTL1-WDR4. Nature 613, 391–397 (2023).
Orellana, E. A. et al. METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation. Mol. Cell 81, 3323–3338.e14 (2021).
Blaze, J. et al. Neuronal Nsun2 deficiency produces tRNA epitranscriptomic alterations and proteomic shifts impacting synaptic signaling and behavior. Nat. Commun. 12, 4913 (2021).
Abbasi-Moheb, L. et al. Mutations in NSUN2 cause autosomal-recessive intellectual disability. Am. J. Hum. Genet. 90, 847–855 (2012).
Eisenberg, E. & Levanon, E. Y. A-to-I RNA editing — immune protector and transcriptome diversifier. Nat. Rev. Genet. 19, 473–490 (2018).
Hideyama, T. et al. Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol. Dis. 45, 1121–1128 (2012).
Gaisler-Salomon, I. et al. Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer’s disease. Neurobiol. Aging 35, 1785–1791 (2014).
Xie, Y. et al. The modified RNA base acp3U is an attachment site for N-glycans in glycoRNA. Cell 187, 5228–5237 (2024).
Flynn, R. A. et al. Small RNAs are modified with N-glycans and displayed on the surface of living cells. Cell 184, 3109–3124.e22 (2021).
Filippova, N. et al. The RNA-binding protein HuR promotes glioma growth and treatment resistance. Mol. Cancer Res. 9, 648–659 (2011).
Guo, X., Connick, M. C., Vanderhoof, J., Ishak, M. A. & Hartley, R. S. MicroRNA-16 modulates HuR regulation of cyclin E1 in breast cancer cells. Int. J. Mol. Sci. 16, 7112–7132 (2015).
Gutschner, T. et al. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma. Hepatology 59, 1900–1911 (2014).
Dai, N. et al. IGF2 mRNA binding protein-2 is a tumor promoter that drives cancer proliferation through its client mRNAs IGF2 and HMGA1. eLife 6, e27155 (2017).
Ye, S., Song, W., Xu, X., Zhao, X. & Yang, L. IGF2BP2 promotes colorectal cancer cell proliferation and survival through interfering with RAF-1 degradation by miR-195. FEBS Lett. 590, 1641–1650 (2016).
Hämmerle, M. et al. Posttranscriptional destabilization of the liver-specific long noncoding RNA HULC by the IGF2 mRNA-binding protein 1 (IGF2BP1). Hepatology 58, 1703–1712 (2013).
Mizutani, R. et al. Oncofetal protein IGF2BP3 facilitates the activity of proto-oncogene protein eIF4E through the destabilization of EIF4E-BP2 mRNA. Oncogene 35, 3495–3502 (2016).
Li, M., Chen, H. & Wu, T. LIN28: a cancer stem cell promoter for immunotherapy in head and neck squamous cell carcinoma. Oral Oncol. 98, 92–95 (2019).
Rastogi, S. K., Gupta, B. N., Husain, T. & Mathur, N. Cardio-respiratory studies on glass bangle workers. Int. Arch. Occup. Environ. Health 61, 487–493 (1989).
Vo, D. T. et al. The oncogenic RNA-binding protein Musashi1 is regulated by tumor suppressor miRNAs. RNA Biol. 8, 817–828 (2011).
Velasco, M. X. et al. Antagonism between the RNA-binding protein Musashi1 and miR-137 and its potential impact on neurogenesis and glioblastoma development. RNA 25, 768–782 (2019).
Vo, D. T. et al. The oncogenic RNA-binding protein Musashi1 is regulated by HuR via mRNA translation and stability in glioblastoma cells. Mol. Cancer Res. 10, 143–155 (2012).
Niu, J., Zhao, X., Liu, Q. & Yang, J. Knockdown of MSI1 inhibited the cell proliferation of human osteosarcoma cells by targeting p21 and p27. Oncol. Lett. 14, 5271–5278 (2017).
Fox, R. G. et al. Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. Nature 534, 407–411 (2016).
Nabors, L. B., Gillespie, G. Y., Harkins, L. & King, P. H. HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3′ untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res. 61, 2154–2161 (2001).
Feng, C. et al. Lin28 regulates HER2 and promotes malignancy through multiple mechanisms. Cell Cycle 11, 2486–2494 (2012).
Roos, M. et al. A small-molecule inhibitor of lin28. ACS Chem. Biol. 11, 2773–2781 (2016).
Golan-Gerstl, R. et al. Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res. 71, 4464–4472 (2011).
Yin, D., Kong, C. & Chen, M. Effect of hnRNPA2/B1 on the proliferation and apoptosis of glioma U251 cells via the regulation of AKT and STAT3 pathways. Biosci. Rep. 40, BSR20190318 (2020).
Deng, J. et al. Effects of hnRNP A2/B1 knockdown on inhibition of glioblastoma cell invasion, growth and survival. Mol. Neurobiol. 53, 1132–1144 (2016).
Fuentes-Fayos, A. C. et al. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3. Brain 143, 3273–3293 (2020).
Yang, Q., Zhao, J., Zhang, W., Chen, D. & Wang, Y. Aberrant alternative splicing in breast cancer. J. Mol. Cell Biol. 11, 920–929 (2019).
Du, J.-X. et al. Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1. J. Exp. Clin. Cancer Res. 40, 171 (2021).
Yu, Y. & Fang, L. CircRPAP2 regulates the alternative splicing of PTK2 by binding to SRSF1 in breast cancer. Cell Death Discov. 8, 152 (2022).
Liu, J. et al. Prognostic alternative splicing events related splicing factors define the tumor microenvironment and pharmacogenomic landscape in lung adenocarcinoma. Aging 14, 6689–6715 (2022).
He, Q. et al. LINC00924-induced fatty acid metabolic reprogramming facilitates gastric cancer peritoneal metastasis via hnRNPC-regulated alternative splicing of Mnk2. Cell Death Dis. 13, 987 (2022).
Tzelepis, K. et al. A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Rep. 17, 1193–1205 (2016).
Barbieri, I. et al. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature 552, 126–131 (2017).
Vu, L. P. et al. The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat. Med. 23, 1369–1376 (2017).
Paris, J. et al. Targeting the RNA m6A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia. Cell Stem Cell 25, 137–148.e6 (2019).
Tang, W. et al. ALKBH5 promotes PD-L1-mediated immune escape through m6A modification of ZDHHC3 in glioma. Cell Death Discov. 8, 497 (2022).
You, Y. et al. ALKBH5/MAP3K8 axis regulates PD-L1+ macrophage infiltration and promotes hepatocellular carcinoma progression. Int. J. Biol. Sci. 18, 5001–5018 (2022).
Burns, M. B., Temiz, N. A. & Harris, R. S. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 45, 977–983 (2013).
Baker, A. R. & Slack, F. J. ADAR1 and its implications in cancer development and treatment. Trends Genet. 38, 821–830 (2022).
Paz-Yaacov, N. et al. Elevated RNA editing activity is a major contributor to transcriptomic diversity in tumors. Cell Rep. 13, 267–276 (2015).
Anadón, C. et al. Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis. Oncogene 35, 4407–4413 (2016).
Ishizuka, J. J. et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature 565, 43–48 (2019).
Moser, J. C., Papadopoulos, K. P., Ahnert, J. R., Ofir-Rosenfeld, Y. & Holz, J.-B.STC15-22101 Study Team Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL-3 inhibitor, in patients with advanced malignancies. J. Clin. Oncol. 42, 2586 (2024).
Wang, E. et al. Targeting an RNA-binding protein network in acute myeloid leukemia. Cancer Cell 35, 369–384 (2019).
Haferlach, T. et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241–247 (2014).
Malcovati, L. et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood 126, 233–241 (2015).
Papaemmanuil, E. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616–3627 (2013).
Feng, L. et al. Cleavage stimulation factor subunit 2: function across cancers and potential target for chemotherapeutic drugs. Front. Pharmacol. 13, 852469 (2022).
Huang, Z. et al. Prognostic significance and tumor immune microenvironment heterogenicity of m5C RNA methylation regulators in triple-negative breast cancer. Front. Cell Dev. Biol. 9, 657547 (2021).
Zhang, C. et al. Cancer mutations rewire the RNA methylation specificity of METTL3-METTL14. Sci. Adv. 10, eads4750 (2024).
Miyake, K. et al. A cancer-associated METTL14 mutation induces aberrant m6A modification, affecting tumor growth. Cell Rep. 42, 112688 (2023).
Zheng, F. et al. Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer. Biomark Res. 9, 28 (2021).
Qin, Q., Fang, D. L., Zhou, W., Meng, Y. & Wei, J. Classification and immune invasion analysis of breast cancer based on m6A genes. Ann. Transl. Med. 9, 1418 (2021).
Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941–D947 (2019).
Brunetti, L. et al. Mutant NPM1 maintains the leukemic state through HOX expression. Cancer Cell 34, 499–512.e9 (2018).
Grummitt, C. G., Townsley, F. M., Johnson, C. M., Warren, A. J. & Bycroft, M. Structural consequences of nucleophosmin mutations in acute myeloid leukemia. J. Biol. Chem. 283, 23326–23332 (2008).
Antonescu, C. R. et al. Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma: absence in predominantly myxoid well-differentiated liposarcomas. J. Mol. Diagn. 2, 132–138 (2000).
Shing, D. C. et al. FUS/ERG gene fusions in Ewing’s tumors. Cancer Res. 63, 4568–4576 (2003).
Ichikawa, H., Shimizu, K., Hayashi, Y. & Ohki, M. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res. 54, 2865–2868 (1994).
Waters, B. L., Panagopoulos, I. & Allen, E. F. Genetic characterization of angiomatoid fibrous histiocytoma identifies fusion of the FUS and ATF-1 genes induced by a chromosomal translocation involving bands 12q13 and 16p11. Cancer Genet. Cytogenet. 121, 109–116 (2000).
Storlazzi, C. T. et al. Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma. Hum. Mol. Genet. 12, 2349–2358 (2003).
Liu, S. V., Nagasaka, M., Atz, J., Solca, F. & Müllauer, L. Oncogenic gene fusions in cancer: from biology to therapy. Signal Transduct. Target. Ther. 10, 111 (2025).
Dimitrova-Paternoga, L., Jagtap, P. K. A., Chen, P. C. & Hennig, J. Integrative structural biology of protein-RNA complexes. Structure 28, 6–28 (2020).
Minuesa, G. et al. A 1536-well fluorescence polarization assay to screen for modulators of the MUSASHI family of RNA-binding proteins. Comb. Chem. High Throughput Screen. 17, 596–609 (2014).
Mahapatra, L., Andruska, N., Mao, C., Le, J. & Shapiro, D. J. A novel IMP1 inhibitor, BTYNB, targets c-Myc and inhibits melanoma and ovarian cancer cell proliferation. Transl. Oncol. 10, 818–827 (2017).
Borowski, P. et al. ATP-binding domain of NTPase/helicase as a target for hepatitis C antiviral therapy. Acta Biochim. Pol. 47, 173–180 (2000).
Zhang, N. et al. Potent inhibition of NTPase/helicase of the West Nile virus by ring-expanded (‘fat’) nucleoside analogues. J. Med. Chem. 46, 4776–4789 (2003).
Zhang, N. et al. Ring-expanded (‘fat’) nucleoside and nucleotide analogues exhibit potent in vitro activity against Flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus. J. Med. Chem. 46, 4149–4164 (2003).
Yedavalli, V. S. R. K. et al. Ring expanded nucleoside analogues inhibit RNA helicase and intracellular human immunodeficiency virus type 1 replication. J. Med. Chem. 51, 5043–5051 (2008).
Rotili, D. et al. Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level. J. Med. Chem. 54, 3091–3096 (2011).
Maga, G. et al. Second-generation inhibitors of the cellular ATPase DDX3 with improved anti-HIV activity: synthesis, structure-activity relationship analysis, cytotoxicity studies, and target validation. ChemMedChem 6, 1371–1389 (2011).
Maga, G. et al. Pharmacophore modeling and molecular docking led to the discovery of inhibitors of human immunodeficiency virus-1 replication targeting the human cellular aspartic acid-glutamic acid-alanine-aspartic acid box polypeptide 3. J. Med. Chem. 51, 6635–6638 (2008).
Radi, M. et al. Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: towards the next generation HIV-1 inhibitors. Bioorg Med. Chem. Lett. 22, 2094–2098 (2012).
Hood, K. A., West, L. M., Northcote, P. T., Berridge, M. V. & Miller, J. H. Induction of apoptosis by the marine sponge (Mycale) metabolites, mycalamide A and pateamine. Apoptosis 6, 207–219 (2001).
Dang, Y. et al. Inhibition of nonsense-mediated mRNA decay by the natural product pateamine A through eukaryotic initiation factor 4AIII. J. Biol. Chem. 284, 23613–23621 (2009).
Bordeleau, M.-E. et al. Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. Proc. Natl Acad. Sci. USA 102, 10460–10465 (2005).
Bordeleau, M.-E. et al. RNA-mediated sequestration of the RNA helicase eIF4A by pateamine A inhibits translation initiation. Chem. Biol. 13, 1287–1295 (2006).
Chen, R. et al. Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. Leukemia 33, 1663–1674 (2019).
Kuznetsov, G. et al. Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A. Mol. Cancer Ther. 8, 1250–1260 (2009).
Bordeleau, M.-E. et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J. Clin. Invest. 118, 2651–2660 (2008).
Vijaya Saradhi, U. V. R. et al. Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry. AAPS J. 13, 347–356 (2011).
Lucas, D. M. et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 113, 4656–4666 (2009).
Cencic, R. et al. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS ONE 4, e5223 (2009).
Lindqvist, L. et al. Selective pharmacological targeting of a DEAD box RNA helicase. PLoS ONE 3, e1583 (2008).
Bordeleau, M.-E. et al. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat. Chem. Biol. 2, 213–220 (2006).
Cencic, R. et al. Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc. Natl Acad. Sci. USA 108, 1046–1051 (2011).
Moerke, N. J. et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128, 257–267 (2007).
Naineni, S. K. et al. A comparative study of small molecules targeting eIF4A. RNA 26, 541–549 (2020).
Chen, M. et al. Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A. Cell Chem. Biol. 28, 475–486.e8 (2021).
Lee, T. & Pelletier, J. The biology of DHX9 and its potential as a therapeutic target. Oncotarget 7, 42716–42739 (2016).
Singh, A. et al. Development of a specific and potent IGF2BP1 inhibitor: a promising therapeutic agent for IGF2BP1-expressing cancers. Eur. J. Med. Chem. 263, 115940 (2024).
Wallis, N. et al. AVJ16 inhibits lung carcinoma by targeting IGF2BP1. Oncogene 44, 3239–3254 (2025).
Liu, Y. et al. Allosteric regulation of IGF2BP1 as a novel strategy for the activation of tumor immune microenvironment. ACS Cent. Sci. 8, 1102–1115 (2022).
Minuesa, G. et al. Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia. Nat. Commun. 10, 2691 (2019).
Keller, C. G. et al. An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion. Nat. Commun. 13, 1150 (2022).
Pisera, A., Campo, A. & Campo, S. Structure and functions of the translation initiation factor eIF4E and its role in cancer development and treatment. J. Genet. Genom. 45, 13–24 (2018).
Li, Q. & Kang, C. Targeting RNA-binding proteins with small molecules: perspectives, pitfalls and bifunctional molecules. FEBS Lett. 597, 2031–2047 (2023).
Wan, X. et al. Discovery of lysine-targeted eIF4E inhibitors through covalent docking. J. Am. Chem. Soc. 142, 4960–4964 (2020).
Yankova, E. et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 593, 597–601 (2021).
Arora, M. et al. Selective inhibition of the m6a RNA reader, YTHDC1, as a novel therapeutic strategy for MYC-driven acute myeloid leukemia. Blood 144, 2207 (2024).
Feng, G. et al. Small molecule inhibitors targeting m6A regulators. J. Hematol. Oncol. 17, 30 (2024).
Huang, Y. et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell 35, 677–691 (2019).
Chen, J. et al. Inhibition of ALKBH5 attenuates I/R-induced renal injury in male mice by promoting Ccl28 m6A modification and increasing Treg recruitment. Nat. Commun. 14, 1161 (2023).
Sun, R.-X. et al. ALKBH5 causes retinal pigment epithelium anomalies and choroidal neovascularization in age-related macular degeneration via the AKT/mTOR pathway. Cell Rep. 42, 112779 (2023).
Li, N. et al. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc. Natl Acad. Sci. USA 117, 20159–20170 (2020).
Takahashi, H. et al. Discovery of two novel ALKBH5 selective inhibitors that exhibit uncompetitive or competitive type and suppress the growth activity of glioblastoma multiforme. Chem. Biol. Drug Des. 100, 1–12 (2022).
Selberg, S., Seli, N., Kankuri, E. & Karelson, M. Rational design of novel anticancer small-molecule RNA m6A demethylase ALKBH5 inhibitors. ACS Omega 6, 13310–13320 (2021).
Lai, G.-Q. et al. A covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO. RSC Chem. Biol. 5, 335–343 (2024).
Malacrida, A. et al. 3D proteome-wide scale screening and activity evaluation of a new ALKBH5 inhibitor in U87 glioblastoma cell line. Bioorg. Med. Chem. 28, 115300 (2020).
Malacrida, A. et al. MV1035 overcomes temozolomide resistance in patient-derived glioblastoma stem cell lines. Biology 11, 115370 (2022).
Kaur, T., Menon, A. & Garner, A. L. Synthesis of 7-benzylguanosine cap-analogue conjugates for eIF4E targeted degradation. Eur. J. Med. Chem. 166, 339–350 (2019).
Ghidini, A., Clery, A., Halloy, F., Allain, F. H. T. & Hall, J. RNA-PROTACs: degraders of RNA-binding proteins. Angew. Chem. Int. Ed. 60, 3163–3169 (2021).
Xu, Y. et al. A heterobifunctional molecule recruits cereblon to an RNA scaffold and activates its PROTAC function. Cell Rep. Phys. Sci. 3, 101064 (2022).
Schreiber, S. L. Molecular glues and bifunctional compounds: therapeutic modalities based on induced proximity. Cell Chem. Biol. 31, 1050–1063 (2024).
Kassabri, L. & Benhamou, R. I. Druglike molecular degraders of the oncogenic RNA-binding protein HuR. JACS Au 5, 3879–3891 (2025).
Faust, T. B. et al. Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15. Nat. Chem. Biol. 16, 7–14 (2020).
Bewersdorf, J. P. et al. E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. Leukemia 37, 2512–2516 (2023).
Lu, X. et al. Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer. Nature 655, 780–789 (2026).
Graziano, V. R. et al. RNA N-glycosylation enables immune evasion and homeostatic efferocytosis. Nature 645, 784–792 (2025).
Li, Z. et al. Cell-surface RNA forms ternary complex with RNA-binding proteins and heparan sulfate to recruit immune receptors. Mol. Cell 85, 4633–4650.e11 (2025).
Lerner, M. R., Boyle, J. A., Mount, S. M., Wolin, S. L. & Steitz, J. A. Are snRNPs involved in splicing? Nature 283, 220–224 (1980).
Gillissen, M. A. et al. AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses. Blood 131, 131–143 (2018).
Wang, D. et al. AAgAtlas 1.0: a human autoantigen database. Nucleic Acids Res. 45, D769–D776 (2017).
Dou, D. R. et al. Xist ribonucleoproteins promote female sex-biased autoimmunity. Cell 187, 733–749.e16 (2024).
Christensen, S. R. et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417–428 (2006).
Brown, G. J. et al. TLR7 gain-of-function genetic variation causes human lupus. Nature 605, 349–356 (2022).
Deane, J. A. et al. Control of Toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 27, 801–810 (2007).
Williams, S. G. & Wolin, S. L. The autoantigen repertoire and the microbial RNP world. Trends Mol. Med. 27, 422–435 (2021).
Porat, J. & Flynn, R. A. Cell surface RNA biology: new roles for RNA binding proteins. Trends Biochem. Sci. 50, 402–416 (2025).
Jaeggi, E., Laskin, C., Hamilton, R., Kingdom, J. & Silverman, E. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus: a prospective study of 186 antibody-exposed fetuses and infants. J. Am. Coll. Cardiol. 55, 2778–2784 (2010).
Joseph, C. G. et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343, 152–157 (2014).
Dai, L. et al. Using serological proteome analysis to identify serum anti-nucleophosmin 1 autoantibody as a potential biomarker in European-American and African-American patients with prostate cancer. Prostate 76, 1375–1386 (2016).
Scholz, A. et al. Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101. Proc. Natl Acad. Sci. USA 119, e2123483119 (2022).
Schnider, B. et al. HumanLectome, an update of UniLectin for the annotation and prediction of human lectins. Nucleic Acids Res. 52, D1683–D1693 (2024).
Holmskov, U., Thiel, S. & Jensenius, J. C. Collections and ficolins: humoral lectins of the innate immune defense. Annu. Rev. Immunol. 21, 547–578 (2003).
Lepenies, B. & Lang, R. Editorial: Lectins and their ligands in shaping immune responses. Front. Immunol. 10, 2379 (2019).
Carpentier, M. et al. Nucleolin undergoes partial N- and O-glycosylations in the extranuclear cell compartment. Biochemistry 44, 5804–5815 (2005).
Dobie, C. & Skropeta, D. Insights into the role of sialylation in cancer progression and metastasis. Br. J. Cancer 124, 76–90 (2021).
Tayyari, F. et al. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat. Med. 17, 1132–1135 (2011).
Calnan, B. J., Biancalana, S., Hudson, D. & Frankel, A. D. Analysis of arginine-rich peptides from the HIV Tat protein reveals unusual features of RNA-protein recognition. Genes Dev. 5, 201–210 (1991).
Clause, K. C. & Barker, T. H. Extracellular matrix signaling in morphogenesis and repair. Curr. Opin. Biotechnol. 24, 830–833 (2013).
Huang, J. et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct. Target. Ther. 6, 153 (2021).
Chai, P. et al. “GlycoRNA Complexed with Heparan Sulfate Regulates VEGF-A Signalling.” Nature 651, 808–818 (2026).
Semenkovich, C. F., Ostlund, R. E., Olson, M. O. & Yang, J. W. A protein partially expressed on the surface of HepG2 cells that binds lipoproteins specifically is nucleolin. Biochemistry 29, 9708–9713 (1990).
Reyes-Reyes, E. M. & Akiyama, S. K. Cell-surface nucleolin is a signal transducing P-selectin binding protein for human colon carcinoma cells. Exp. Cell Res. 314, 2212–2223 (2008).
Tate, A. et al. Met-independent hepatocyte growth factor-mediated regulation of cell adhesion in human prostate cancer cells. BMC Cancer 6, 197 (2006).
Destouches, D. et al. Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin. PLoS ONE 3, e2518 (2008).
Losfeld, M.-E. et al. The cell surface expressed nucleolin is a glycoprotein that triggers calcium entry into mammalian cells. Exp. Cell Res. 315, 357–369 (2009).
Fujiki, H., Watanabe, T. & Suganuma, M. Cell-surface nucleolin acts as a central mediator for carcinogenic, anti-carcinogenic, and disease-related ligands. J. Cancer Res. Clin. Oncol. 140, 689–699 (2014).
Laber, D. A. et al. Update on the first phase I study of AGRO100 in advanced cancer. J. Clin. Oncol. 23, 3064 (2005).
Stuart, R. K. et al. Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML). J. Clin. Oncol. 27, 7019–7019 (2009).
Rosenberg, J. E. et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest. New Drugs 32, 178–187 (2014).
Kitagawa, S. et al. Highly diverged U4 and U6 small nuclear RNAs required for splicing rare AT-AC introns. Science 273, 1824–1832 (1996).
Chmielowski, B. et al. Elucidation of the role of nucleolin as a cell surface receptor for nucleic acid-based adjuvants. NPJ Vaccines 7, 115 (2022).
Kantarjian, H. et al. Interim update of the ATRC-101 phase 1b trial in advanced solid tumors. J. Clin. Oncol. 41, 2505 (2023).
Lambert, J. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836–847 (2017).
Lambert, J. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica 104, 113–119 (2019).
Mayor, S., Presley, J. F. & Maxfield, F. R. Sorting of membrane components from endosomes and subsequent recycling to the cell surface occurs by a bulk flow process. J. Cell Biol. 121, 1257–1269 (1993).
Fu, Z., Li, S., Han, S., Shi, C. & Zhang, Y. Antibody drug conjugate: the ‘biological missile’ for targeted cancer therapy. Signal Transduct. Target. Ther. 7, 93 (2022).
Fischer, J. et al. CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J. Immunother. 40, 187–195 (2017).
Fioretti, S., Matson, C. A., Rosenberg, K. M. & Singh, N. J. Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19. Cancer Immunol. Immunother. 72, 257–264 (2023).
Chao, K. S. C. et al. A novel therapeutic approach using ENO1-specific CAR-NK cells to target KRAS-mutated cancers. Int. J. Radiat. Oncol. Biol. Phys. 123, S80 (2025).
Fujino, T. et al. Development of CAR T cells targeting a surface RNA-binding protein for the treatment of acute leukemias. Cancer Discov. OF1–OF23 (2026).
Simon Davis, D. A. & Parish, C. R. Heparan sulfate: a ubiquitous glycosaminoglycan with multiple roles in immunity. Front. Immunol. 4, 470 (2013).
Wu, K. et al. Design of intrinsically disordered region binding proteins. Science 389, eadr8063 (2025).
Liu, C. et al. Diffusing protein binders to intrinsically disordered proteins. Nature 644, 809–817 (2025).
Huang, B. et al. Designed endocytosis-inducing proteins degrade targets and amplify signals. Nature 638, 796–804 (2025).
Zhang, D. et al. Transferrin receptor targeting chimeras for membrane protein degradation. Nature 638, 787–795 (2025).
Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291–297 (2020).
Biernacki, M. A. et al. SF3B1K700E neoantigen is a CD8+ T-cell target shared across human myeloid neoplasms. Cancer Immunol. Res. 13, 1391–1404 (2025).
Biernacki, M. A. et al. Discovery of U2AF1 neoantigens in myeloid neoplasms. J. Immunother. Cancer 11, e007490 (2023).
Wang, Y.-Z. et al. Discovery of pyrazolo[1,5-a]pyrimidine derivative as a novel and selective ALKBH5 inhibitor for the treatment of AML. J. Med. Chem. 66, 15944–15959 (2023).
Ross, N. T. et al. CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing’s sarcoma. Nat. Chem. Biol. 16, 50–59 (2020).
Pelster, M. et al. Trial in progress: First-in-human study of ATX-559, an oral inhibitor of DHX9, in patients with advanced or metastatic solid tumors, and molecularly defined cancers. J. Clin. Oncol. 43, TPS3181 (2025).
Ernst, J. T. et al. Design of development candidate eFT226, a first in class inhibitor of eukaryotic initiation factor 4A RNA helicase. J. Med. Chem. 63, 5879–5955 (2020).
Pianka, S. T. et al. D-2-HG inhibits IDH1mut glioma growth via FTO inhibition and resultant m6a hypermethylation. Cancer Res. Commun. 4, 876–894 (2024).
Kathman, S. G. et al. Remodeling oncogenic transcriptomes by small molecules targeting NONO. Nat. Chem. Biol. 19, 825–836 (2023).
Mollasalehi, N. et al. An allosteric modulator of RNA binding targeting the N-terminal domain of TDP-43 yields neuroprotective properties. ACS Chem. Biol. 15, 2854–2859 (2020).
François-Moutal, L. et al. Small molecule targeting TDP-43’s RNA recognition motifs reduces locomotor defects in a Drosophila model of amyotrophic lateral sclerosis (ALS). ACS Chem. Biol. 14, 2006–2013 (2019).
McPhie, K. A. et al. Discovery and optimisation of a covalent ligand for TRIM25 and its application to targeted protein ubiquitination. Chem. Sci. 16, 10432–10443 (2025).
Kotake, Y. et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat. Chem. Biol. 3, 570–575 (2007).
Kaida, D. et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat. Chem. Biol. 3, 576–583 (2007).
Seiler, M. et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat. Med. 24, 497–504 (2018).
Eskens, F. A. L. M. et al. Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin. Cancer Res. 19, 6296–6304 (2013).
Steensma, D. P. et al. Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia 35, 3542–3550 (2021).
Hong, D. S. et al. A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest. New Drugs 32, 436–444 (2014).
Lazear, M. R. et al. Proteomic discovery of chemical probes that perturb protein complexes in human cells. Mol. Cell 83, 1725–1742.e12 (2023).
Jagtap, P. K. A. et al. Identification of phenothiazine derivatives as UHM-binding inhibitors of early spliceosome assembly. Nat. Commun. 11, 5621 (2020).
Chatrikhi, R. et al. A synthetic small molecule stalls pre-mRNA splicing by promoting an early-stage U2AF2-RNA complex. Cell Chem. Biol. 28, 1145–1157.e6 (2021).
Sabzvar, M. K. et al. An inhibitor of UHM splicing factors exerts anti-leukemic activity by altering cell cycle progression and reducing lysosome acidification. Cell Signal. 136, 112112 (2025).
Iwatani-Yoshihara, M. et al. Discovery of allosteric inhibitors targeting the spliceosomal RNA helicase Brr2. J. Med. Chem. 60, 5759–5771 (2017).